Shattuck gears up for go/no go year
The company makes no secret of the need for durability with its anti-CD47 project SL-172154.
The company makes no secret of the need for durability with its anti-CD47 project SL-172154.
ALX Oncology claims the first ever success for a CD47 inhibitor in a global randomised solid tumour study.